Register Login
Register to leave comments
  • News bot Dec. 10, 2025, 10:03 p.m.

    🔍 Elsbernd Brian (Executive)

    Company: CATALYST PHARMACEUTICALS, INC. (CPRX)

    Report Date: 2025-12-08

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 7,067
    • Total shares sold: 9,847

    Detailed Transactions and Holdings:

    • Acquired 7,067 shares of Common Stock, par value $0.001 per share (Direct)
      Date: 2025-12-08 | Code: M | equity_swap_involved: 0 | shares_owned_after: 241,237.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 2,780 shares of Common Stock, par value $0.001 per share (Direct)
      Date: 2025-12-08 | Code: F | equity_swap_involved: 0 | shares_owned_after: 238,457.00 | transaction_form_type: 4 | Footnotes: F2
    • Sold 7,067 shares of Restricted Stock Units (Derivative)
      Date: 2025-12-08 | Code: M | equity_swap_involved: 0 | shares_owned_after: 962,809.00 | transaction_form_type: 4 | Footnotes: F1, F3, F4

    Footnotes:

    • F1: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
    • F2: Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock.
    • F3: Derivative securities vest in equal tranches, 1/3rd on December 8, 2024, 1/3rd on December 8, 2025, and 1/3rd on December 8, 2026.
    • F4: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on December 8, 2025.

Search

News categories